Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
The yen approaches a 38-year low, Japanese authorities shift to "tactical silence," and the market is vigilant against sudden intervention.

The yen approaches a 38-year low, Japanese authorities shift to "tactical silence," and the market is vigilant against sudden intervention.

BlockBeatsBlockBeats2026/06/22 11:54
Show original

BlockBeats news, on June 22, the Japanese yen against the US dollar briefly touched around 161.7 on Monday, just a step away from its lowest point since 1986 at 161.96. In response to continued depreciation, Japanese authorities have uncharacteristically remained silent, with the market generally believing this is preparation for a "surprise attack" on short sellers.


Finance Minister Katsuyuki Katayama downplayed the situation on Monday by merely saying "will respond to exchange rate fluctuations in a timely manner," with noticeably softer wording. Jun Mitsumura, considered the core signal for intervention, has been publicly silent since early May—he had issued a "final warning" before the intervention at the end of April. According to informed sources, since previous overly transparent warnings allowed speculators to exit early, the authorities are now intentionally shifting to a surprise mode to maximize the effect of intervention.


The chief FX strategist at Mitsubishi UFJ Morgan Stanley Securities pointed out that under the cover of the lack of urgency in official rhetoric, sudden intervention will have a stronger impact. The latest CFTC data shows net short positions on the yen have surged to 145,818 contracts, the highest since July 2024, with speculative forces highly concentrated.


On inflation pressure, Bank of Japan Deputy Governor Shinichi Himino warned the parliament on Monday that there is a risk of price increases deviating significantly from the 2% target, and if continued yen depreciation pushes up import costs, the risk of the central bank "acting too late" should not be ignored. Analysts pointed out that the current market positions are overstretched and numb due to official silence, so once intervention begins its effectiveness will be multiplied geometrically.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released

October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)

路透社•2026/10/06 07:26